Tesamorelin vs Mod-GRF (1-29).

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH/GRF 1-44), stabilized by a trans-3-hexenoic acid group attached to its N-terminus. It is one of the few research peptides in its class that holds full FDA approval, marketed as Egrifta (and the reformulated Egrifta SV / Egrifta WR) by Theratechnologies for a narrow, specific indication. Originally designated TH9507, it is a secretagogue rather than a hormone itself.

Mod GRF 1-29 (commonly sold as "CJC-1295 without DAC") is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It is the same tetra-substituted GHRH(1-29) peptide backbone used in CJC-1295, but it lacks the maleimido "Drug Affinity Complex" (DAC) linker that the long-acting form carries, so it behaves as a short-acting GHRH secretagogue. Its parent fragment, native GHRH(1-29) ("sermorelin"), retains essentially the full GH-releasing activity of the 44-residue hormone, and the four engineered substitutions are added to slow enzymatic breakdown.

Tesamorelin binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of the body's own growth hormone (GH), which in turn raises hepatic and circulating insulin-like growth factor-1 (IGF-1). Because it works upstream by amplifying endogenous GH secretion, it largely preserves physiological feedback and pulsatility, unlike direct exogenous GH administration. The N-terminal hexenoyl modification confers resistance to degradation (including by dipeptidyl peptidase-IV) and extends its half-life relative to native GHRH. The downstream rise in GH/IGF-1 drives lipolysis, with a notable effect on visceral (intra-abdominal) adipose tissue.

Like endogenous GHRH, the peptide binds the GHRH receptor on anterior-pituitary somatotrophs, raising intracellular cAMP and triggering pulsatile synthesis and release of growth hormone, which in turn drives hepatic IGF-1 production. The four amino-acid substitutions relative to native GHRH(1-29), typically described as D-Ala at position 2, Gln8, Ala15, and Leu27, are intended to resist degradation, with the D-alanine substitution at position 2 specifically blocking cleavage by dipeptidyl peptidase-IV (DPP-IV), the main enzyme that rapidly inactivates GHRH. Because it has no albumin-binding DAC tether, it is cleared quickly and is described as producing brief, pulse-like GH stimulation rather than the sustained "GH bleed" seen with the DAC version. It is mechanistically a secretagogue: it prompts the pituitary's own GH, rather than supplying GH directly.

Human evidence is unusually strong for one specific population: HIV patients with lipodystrophy. Two pivotal phase 3 randomized, placebo-controlled trials and their pooled analysis (Falutz et al., JAIDS 2010 and J Clin Endocrinol Metab 2010) showed roughly a 15-18% reduction in visceral adipose tissue over 26 weeks, with regain after discontinuation, supporting the FDA approval. Stanley et al. (JAMA 2014; PMID 25038357) and a randomized NAFLD trial (Stanley et al., Lancet HIV 2019; PMID 31611038) further demonstrated reductions in liver fat and a lower rate of fibrosis progression in HIV-associated fatty liver disease. Crucially, nearly all rigorous human data come from HIV-positive cohorts; use for general anti-aging, body recomposition, or NAFLD in HIV-negative people is extrapolation and has not been established in large controlled trials. Subcutaneous fat and total weight are largely unaffected, and effects reverse when treatment stops.

The well-known human trials in this family, Teichman et al. (JCEM, 2006), Ionescu & Frohman (JCEM, 2006), and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), all studied CJC-1295 WITH DAC, the long-acting albumin-binding version, not the no-DAC Mod GRF 1-29; Alba et al. (2006) used a GHRH-knockout mouse model. There is no robust, peer-reviewed human clinical trial of Mod GRF 1-29 (the no-DAC peptide) under that name establishing efficacy or safety, so claims about it are largely inferred from GHRH/sermorelin pharmacology and from the DAC-form data rather than directly tested. The unmodified parent peptide, sermorelin/GHRH(1-29), was an FDA-approved diagnostic and pediatric GH agent and is the best-characterized human reference point. Most published mentions of the no-DAC compound itself come from anti-doping analytical chemistry (e.g., Henninge et al., Drug Test Anal, 2010, identifying CJC-1295 in an illicit preparation), which characterize the molecule but not its clinical effects. Honest bottom line: the human-versus-preclinical gap is wide here, and the short-acting form is plausible by analogy but essentially unproven in controlled human studies.

The most consistent documented concerns are glucose-related: because it raises GH/IGF-1, tesamorelin can worsen insulin sensitivity and glucose tolerance, and IGF-1 levels are monitored in clinical practice. Common adverse effects in trials included injection-site reactions, arthralgia, myalgia, peripheral edema, and paresthesia; hypersensitivity reactions have occurred. It is contraindicated in pregnancy and in people with active malignancy, since elevated IGF-1 is a theoretical tumor-growth concern, and in those with disrupted hypothalamic-pituitary axis (e.g., pituitary tumor/surgery, head irradiation). The NIH LiverTox database assigns it a low likelihood of causing clinically apparent liver injury. Long-term safety beyond the trial windows, and safety in non-HIV populations, remains poorly characterized.

Documented safety data specific to Mod GRF 1-29 are minimal because controlled human trials of the no-DAC peptide are lacking; what is known is extrapolated from GHRH analogs broadly. In studies of related GHRH analogs and sermorelin, injection-site reactions (redness, swelling), flushing, and headache are the most commonly reported effects, and any sustained elevation of the GH/IGF-1 axis carries theoretical concerns including fluid retention, joint discomfort, insulin resistance/altered glucose handling, and uncertainty about long-term proliferative risk because IGF-1 is mitogenic. A major real-world hazard is that material sold under this name is research-grade and unregulated, so purity, identity, sterility, and contamination are not assured; anti-doping case reports document the compound appearing in mislabeled or "unknown" pharmaceutical preparations. Interactions with somatostatin tone, other secretagogues, and underlying endocrine or oncologic conditions are not well characterized, and long-term human safety is simply unknown.

FDA-approved (2010, as Egrifta; reformulated as Egrifta SV in 2019 and the F8 formulation Egrifta WR in 2023) solely to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label, and it is a prescription drug, not a dietary supplement.

Mod GRF 1-29 / CJC-1295 without DAC is not approved by the FDA or any major regulator for any indication and is an investigational/research-use-only compound; its unmodified parent, sermorelin, was previously FDA-approved but has been commercially discontinued. As a GHRH analog it falls under the World Anti-Doping Agency (WADA) Prohibited List class S2 (peptide hormones / growth factors and related substances) and is banned in sport at all times.